John F. Chappell rejoins Plexus Ventures as Special Advisor
November 17, 2007 (PRLEAP.COM) Health NewsPhiladelphia, Pennsylvania, November 2007 – Plexus Ventures LLC, the leading pharmaceutical business development consultancy, announced today that John F. Chappell has joined the firm as Special Advisor. Mr. Chappell founded Plexus Ventures in 1990 following 28 years with SmithKlineBeecham where he served in an array of senior executive positions, including Chairman, Pharmaceuticals. He brings vast pharmaceutical commercial experience to the team as well as strong strategic skills which will aid Plexus Ventures’ clients.
Mr. Chappell has served as a member of the Board of Directors of Salix Pharmaceuticals since 1993 and was named Chairman of the Board in September 2003. He is the Chairman of the Bryn Mawr Hospital Foundation and a Board Member of the Main Line Health Systems Board. John Chappell holds a B.A. from Harvard University and a Certificate from the University of Pennsylvania, Wharton School Graduate Evening Program.
Bob Moran, Mr. Chappell’s long-time colleague at SmithKline Beecham and Plexus Ventures said: “We are thrilled to welcome John Chappell back to Plexus Ventures. While in retirement from Plexus Ventures for the past few years, John has always served as informal counsel and advisor to our firm as it has grown and diversified. John will focus his efforts on developing new client relationships for Plexus and providing our clients with strategic guidance toward achieving their growth objectives.” John Chappell explained: “The time was right for a return to active duty at Plexus Ventures. I am proud to rejoin the firm I founded and to work once again with these talented and entrepreneurial professionals.”
About Plexus Ventures
Plexus Ventures, founded in 1990, provides strategic advice, business development and alliance management services to clients in the pharmaceutical, biotechnology and drug delivery industries worldwide. Plexus Ventures assists its clients in the areas of in-licensing, out-licensing, acquisitions, divestitures and strategic partnerships. With offices in Frankfurt, Indianapolis, London, Los Angeles, Milan, Philadelphia, Tokyo and Warsaw, Plexus Ventures possesses the capabilities to effectively serve clients in the United States, Europe and Asia. Plexus Ventures is both well-known and well respected by leading research-based pharmaceutical companies worldwide. For further information, please consult http://www.plexusventures.com.